PDGFRB and triple-negative breast carcinoma: Transcriptome sequencing analysis and in vitro studies showed that ezetimibe could significantly inhibit the expression of PDGFRβ and AKT in triple-negative breast cancer cells, suggesting that ezetimibe may enhance the therapeutic effect of antitumor drugs by inhibiting the PDGFRβ/AKT pathway.